Committee Action
116TH CONGRESS Subcommittee Hearing on Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency On September 26, 2019, the Subcommittee on Health, Employment, Labor, and Pensions (HELP) held a hearing entitled ``Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency,'' which examined the impact of rising prescription drug prices on workers and businesses and the need for greater transparency in health care. The witnesses were Mr. Frederick Isasi, Executive Director, Families USA, Washington, D.C.; Mr. David Mitchell, Founder, Patients for Affordable Drugs, Washington, D.C.; Ms. Bari Talente, Executive Vice President, National Multiple Sclerosis Society, Washington, D.C.; Dr. Mariana Socal, Assistant Scientist, Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, Maryland; Mr. Christopher Holt, Director of Health Care Policy, American Action Forum, Washington, D.C.; and Dr. Craig Garthwaite, Associate Professor of Strategy, Northwestern University Kellogg School of Management, Evanston, Illinois. Full Committee Markup of H.R. 5800, the Ban Surprise Billing Act On February 11, 2020, the Committee met to mark up H.R. 5800, the Ban Surprise Billing Act. The legislation included provisions to amend ERISA to require covered service providers to disclose direct or indirect compensation to responsible plan fiduciaries. The Committee favorably reported the bill, as amended, by a vote of 32 yeas and 13 nays. 117TH CONGRESS Subcommittee Hearing on Lower Drug Costs Now: Expanding Access to Affordable Health Care On May 5, 2021, the HELP Subcommittee held a hearing entitled ``Lower Drug Costs Now: Expanding Access to Affordable Health Care,'' which examined the causes of rising health care costs. The witnesses were Dr. Douglas Holtz-Eakin, President, American Action Forum, Washington, D.C.; Mr. Frederick Isasi, Executive Director, Families USA, Washington, D.C.; Mr. David Mitchell, Founder, Patients for Affordable Drugs, Washington, D.C.; and Dr. Mariana Socal, Assistant Scientist, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. The hearing included discussion regarding how the lack of PBM transparency contributes to higher costs for plans and consumers. 118TH CONGRESS Subcommittee Hearing on Reducing Health Care Costs for Working Americans and Their Families On April 26, 2023, the HELP Subcommittee held a hearing entitled ``Reducing Health Care Costs for Working Americans and Their Families,'' which examined lowering health care costs, including through expanding oversight of PBMs. Witnesses were Mr. Joel White, President, Council for Affordable Health Coverage (CAHC), Washington, D.C.; Mrs. Tracy Watts, Senior Partner, Mercer, Washington, D.C.; Ms. Marcie Strouse, Partner, Capitol Benefits Group, Des Moines, Iowa; and Ms. Sabrina Corlette, J.D., Research Professor and Co-Director, Center on Health Insurance Reforms, Georgetown University McCourt School of Public Policy, Washington, D.C. Subcommittee Hearing on Competition and Transparency: The Pathway Forward for a Stronger Health Care Market On June 21, 2023, the HELP Subcommittee held a hearing entitled ``Competition and Transparency: The Pathway Forward for a Stronger Health Care Market,'' which examined the role of PBMs and the need for transparency. The witnesses were Dr. Gloria Sachdev, President and CEO, Employers' Forum of Indiana, Carmel, Indiana; Ms. Sophia Tripoli, Senior Director of Health Policy and Director of the Center for Affordable Whole-Person Care, Families USA, Washington, D.C.; Mr. Greg Baker, CEO, AffirmedRx, Louisville, Kentucky; Ms. Christine Monahan, Assistant Research Professor, Center on Health Insurance Reforms, Georgetown University McCourt School of Public Policy, Washington, D.C.; and Mr. Juan Carlos ``JC'' Scott, President and CEO, Pharmaceutical Care Management Association, Washington, D.C. The hearing included extensive discussion on the role of PBMs and the impacts of transparency, or lack thereof. Witnesses testified to the impacts of hospital consolidation and acquisition of outpatient departments on raising health care costs for employers and the need to combat unwarranted hospital facility fees applied to outpatient services, including requiring that each separate hospital outpatient facility obtain and use a unique national provider identifier (NPI). Members and witnesses further discussed the need to codify the Transparency in Coverage rule, prohibit gag clauses in contracts between PBMs and TPAs, and require PBMs and TPAs to disclose their compensation. Full Committee Markup of H.R. 4508, the Hidden Fee Disclosure Act, On July 10, 2023, Rep. Joe Courtney (D-CT-2) introduced H.R. 4508, the Hidden Fee Disclosure Act, with Rep. Erin Houchin (R-IN-9) as an original cosponsor. The bill clarifies the application of existing ERISA group health plan disclosure requirements to covered service providers providing services specified in current law and further improves specific disclosure requirements for PBMs and TPAs, particularly with respect to indirect compensation. On July 12, 2023, the Committee met to mark up H.R. 4508 and adopted an Amendment in the Nature of a Substitute offered by Rep. Courtney that made technical corrections to H.R. 4508. The Committee reported the bill favorably, as amended, to the House of Representatives by a vote of 39 yeas and 1 nay. Committee Views PHARMACY BENEFIT MANAGERS PBMs serve as intermediaries between pharmaceutical manufacturers and health insurers, Medicare Part D drug plans, employers, and other payers. PBMs create formularies, negotiate rebates with manufacturers, process claims, create pharmacy networks, and review drug utilization. Although the Congressional Budget Office (CBO) found that PBMs' ability to negotiate larger rebates from manufacturers may have lowered program costs and copays for plan enrollees in Medicare Part D and Medicaid,\2\ in light of rising health care costs, PBMs have faced growing scrutiny of their role in prescription drug costs and spending. --------------------------------------------------------------------------- \2\ https://www.cbo.gov/system/files/2019-05/55151- SupplementalMaterial.pdf. --------------------------------------------------------------------------- By negotiating with drug manufacturers and pharmacies to control drug costs, PBMs have a significant behind-the-scenes impact in determining total drug costs for payers, shaping patients' access to medications, and determining how much pharmacies are paid. PBMs primarily earn profits through administrative fees charged for their services, spread pricing, and shared savings, where the PBM keeps part of the rebates or discounts negotiated with drug manufacturers. There has been increasing concern that the current structure creates a perverse incentive as higher drug list prices often translate into higher compensation for PBMs, who often earn a percentage of reductions negotiated off of the list prices.\3\ --------------------------------------------------------------------------- \3\ Id. --------------------------------------------------------------------------- PBM reimbursement methods can be complex and unclear. Two practices of particular concern are rebate pricing models and spread pricing. One study found a direct correlation between rebate increases and manufacturer price increases: a $1 increase in rebates corresponds with a $1.17 increase in drug list price, suggesting that rebates play a role in increasing list prices.\4\ PBMs may retain manufacturer rebates as profits rather than passing them through to their health plan clients. When health plans lack full transparency and cannot see how much manufacturers paid in rebates, they do not know how much their PBM retained as profits. Spread pricing occurs when PBMs charge health plans and payers more for a prescription drug than what they reimburse to the pharmacy and then they keep the difference. Because neither the plan nor the pharmacy knows what the other side was paid or charged, the practice hides the PBM's margins. --------------------------------------------------------------------------- \4\ https://healthpolicy.usc.edu/research/the-association-between- drug-rebates-and-list-prices/. --------------------------------------------------------------------------- THIRD PARTY ADMINISTRATORS A self-funded group health plan may contract with an entity, known as a third-party administrator (TPA), for the purpose of providing a number of services to the plan. Among these services include claims processing, recordkeeping, communicating with participants and beneficiaries, and ensuring compliance with reporting requirements under ERISA and other laws.\5\ Although often an insurance company, a TPA does not itself act as an insurer with respect to the plan; instead, the plan sponsor bears the financial responsibility of paying claims incurred under the plan. The lack of transparency with respect to the compensation of TPAs has raised concerns that their practices might not be in the best interests of plan sponsors or participants and beneficiaries.\6\ These concerns have prompted bipartisan reforms such as the recent ban on ``gag clauses'' that restrict plan fiduciaries from accessing plan data held by TPAs and other service providers.\7\ --------------------------------------------------------------------------- \5\ https://content.next.westlaw.com/practical-law/document/ I8b78d20587b211e9adfea82903531a62/Third-Party-Administrator- TPA. \6\ https://chirblog.org/questionable-conduct-allegations-insurers- acting-third-party-administrat ors/. \7\ 29 U.S.C. Sec. 1185m. --------------------------------------------------------------------------- ERISA FEE DISCLOSURE REQUIREMENTS Under ERISA, an employee benefit plan may enter into reasonable contracts or arrangements for the provision of certain services ``necessary for the establishment or operation of the plan. . . . if no more than reasonable compensation is paid therefor.'' \8\ This allows a plan to contract with entities such as PBMs, TPAs, brokerage firms, benefits consultants, and others, while ensuring that plan fiduciaries continuously monitor the reasonableness of such arrangements and the compensation received by service providers.\9\ However, without clear disclosures to plan fiduciaries of the services provided and the compensation earned, either directly or indirectly, it is essentially impossible to monitor service providers and ensure they are acting in the best interest of the plan. A lack of meaningful oversight could lead to higher costs for plans and, with respect to indirect compensation, creates the risk that service providers may have conflicts of interest.\10\ --------------------------------------------------------------------------- \8\ 29 U.S.C. Sec. 1108(b)(2). \9\ 29 U.S.C. Sec. 1104(a)(1). \10\ https://www.propublica.org/article/health-insurance-brokers- cost-commissions-bonuses. --------------------------------------------------------------------------- Although no final regulatory action has been taken, there have been several efforts to improve the disclosure of fees with respect to ERISA-covered group health plans. In 2007, the U.S. Department of Labor (the Department) proposed regulations that would have required disclosure of compensation earned by service providers that contract with employee benefit plans, including group health plans.\11\ This would have provided plan fiduciaries with important information from a broad range of service providers, which would have greatly facilitated the ability of fiduciaries to monitor the reasonableness of their contracts.\12\ This proposal was never finalized with respect to group health plans. Similarly, in 2014, the Advisory Council on Employee Welfare and Pension Benefit Plans recommended the Department consider issuing fee disclosure regulations regarding contracts and arrangements between group health plans and PBMs, which would have specifically included rebates received by PBMs as indirect compensation.\13\ To date, the Department has not issued a proposed rule on this topic. --------------------------------------------------------------------------- \11\ https://www.federalregister.gov/documents/2007/12/13/E7-24064/ reasonable-contract-or-arran gement-under-section-408b2-fee-disclosure. \12\ Id. \13\ https://www.dol.gov/sites/dolgov/files/ebsa/about-ebsa/about- us/erisa-advisory-council/2014AC report1.pdf. --------------------------------------------------------------------------- DIRECT AND INDIRECT COMPENSATION DISCLOSURE REQUIREMENTS The No Surprises Act, enacted as part of the Consolidated Appropriations Act, 2021 (CAA),\14\ protected patients from surprise medical bills for emergency and out-of-network services and created a process by which providers and plans could reconcile billing disputes. In addition, the CAA sought to limit growth in health care spending through increased transparency. Importantly, Section 202 of Title II of Division BB of the CAA requires entities providing brokerage and consulting services to disclose direct or indirect compensation to group health plan fiduciaries (a similar provision extended broker disclosure requirements to individual market consumers). This provision amended section 408(b)(2) of ERISA to provide that any ``covered service provider'' that enters into a contract or arrangement with a group health plan must disclose to a responsible plan fiduciary a description of the direct and indirect compensation they expect to receive in connection with the services they provide to the plan.\15\ This disclosure requirement applies to the provision of brokerage services and broadly to entities providing consulting, including the ``development or implementation of'' pharmacy benefit management services and third-party administration services. Although the text of this statute clearly encompasses the activities of TPAs and PBMs, many service providers have failed to comply with the law and may not be providing the required disclosures to plan fiduciaries. --------------------------------------------------------------------------- \14\ Pub. L. No. 116-260 (2020). \15\ ERISA Sec. 408(b)(2), 29 U.S.C. Sec. 1108. --------------------------------------------------------------------------- While the Department's Employee Benefits Security Administration (EBSA) has previously issued guidance that service providers may assess the applicability of these requirements consistent with similar regulations applicable to retirement plans (which explicitly apply to TPAs),\16\ additional action is needed to clarify the scope of entities subject to the requirements under the law. Because higher-cost drugs often offer higher rebates and, in turn, contribute to rising prescription drug spending, detailed disclosures of these and other compensation practices will assist plan fiduciaries in assessing their contracts with service providers. In December 2022, then-Chairman Scott (D-VA-3) and then-Ranking Member Foxx (R-NC-5) of the Committee on Education and Labor sent a bipartisan letter urging EBSA to issue additional, clarifying guidance, but the agency has to date taken no action.\17\ --------------------------------------------------------------------------- \16\ https://www.dol.gov/agencies/ebsa/employers-and-advisers/ guidance/field-assistance-bulletins /2021-03. \17\ https://democrats-edworkforce.house.gov/imo/media/doc/ bipartisan_scott-foxx_letter_to_ebsa_ re_health_transparency.pdf. --------------------------------------------------------------------------- H.R. 4508, THE HIDDEN FEE DISCLOSURE ACT H.R. 4508 will help ensure that plan sponsors and plan fiduciaries have the information they need to make informed choices on behalf of plan participants. By receiving information on the nature and amount of compensation that PBMs and TPAs receive, plan fiduciaries can better evaluate the reasonableness of their compensation and whether PBMs and TPAs are acting in the best interest of the plan. Plans can measure whether savings are being appropriately passed through and can confirm that PBMs and TPAs are not unduly benefitting from rebate decisions at the expense of the plan. H.R. 4508 will improve accountability and competition among PBMs and TPAs and empower plans to make better decisions on behalf of employees, leading to lower spending. H.R. 4508 Section-by-Section Summary Section 1. Short title Section 1 provides that the short title is ``Hidden Fee Disclosure Act.'' Section 2. Clarification of the application of fee disclosure requirements to covered service providers Section 2(a) amends ERISA to clarify that compensation disclosure requirements apply to all services specified in current law. Section 2(b) amends ERISA to provide that direct compensation must be described by service, rather than in the aggregate. Section 3. Strengthening disclosure requirements for PBMs and TPAs Section 3(a) amends ERISA to provide that PBM services provided to a health insurance issuer on behalf of a group health plan shall be considered an indirect furnishing of goods, services, or facilities, thereby ensuring disclosures are provided to responsible plan fiduciaries of fully insured plans. PBM Disclosure Requirements. Section 3(b)(1) requires that PBMs report to responsible plan fiduciaries (as part of disclosure requirements under current law) the following information: All compensation, including fees, rebates, discounts, or price concessions, co-payment offsets, and other remuneration; The amount and form of rebates, discounts, or price concessions that are passed through to the plan sponsor or participants and beneficiaries; The amount of compensation received as a result of the PBM paying less for a drug than the amount charged to the participant or beneficiary; The amount of compensation received from paying pharmacies less than what was charged to the plan or participant or beneficiary; and The amount of compensation expected to be received from drug manufacturers, including compensation gained in exchange for administering the plan, for providing business services and drug utilization data, and for gaining compensation through high rebates or a percentage of the list price. The PBM must report this information when it enters a contract with the plan, and it is required to disclose any changes as soon as practicable but no later than within 60 days. PBM Annual Reporting. Section 3(b)(2) requires that PBMs annually report to responsible plan fiduciaries the following information: All direct and indirect compensation; For each drug covered under the plan, the amount by which the price for the drug paid by the plan exceeds the amount paid to the pharmacy; The total gross spending by the plan on drugs (excluding rebates, discounts, or other price concessions);